The clinical value of tumor burden at diagnosis in Hodgkin lymphoma

Authors

  • Paolo G. Gobbi M.D.,

    Corresponding author
    1. Medicina Interna e Oncologia Medica, Universitá di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy
    • Medicina Interna e Oncologia Medica, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, P. le Golgi no. 2, 27100 Pavia, Italy
    Search for more papers by this author
    • Fax: 011 (39) 0382526223

  • Chiara Broglia M.D.,

    1. Medicina Interna e Oncologia Medica, Universitá di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy
    Search for more papers by this author
  • Giuseppe Di Giulio M.D.,

    1. Istituto di Radiologia, Universitá di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy
    Search for more papers by this author
  • Monica Mantelli M.D.,

    1. Istituto di Radiologia, Universitá di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy
    Search for more papers by this author
  • Paola Anselmo M.D.,

    1. Istituto di Ematologia, Universitá “La Sapienza,” Roma, Italy
    Search for more papers by this author
  • Francesco Merli M.D.,

    1. Divisione di Ematologia, Arcispedale “S. Maria Nuova,” Reggio Emilia, Italy
    Search for more papers by this author
  • Pier L. Zinzani M.D.,

    1. Istituto di Ematologia “L e A. Seragnoli,” Universitá di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
    Search for more papers by this author
  • Gabriele Rossi M.D.,

    1. Istituto di Pediatria, Universitá di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy
    Search for more papers by this author
  • Vincenzo Callea M.D.,

    1. Divisione di Ematologia, Presidio Ospedali Riuniti, Reggio Calabria, Italy
    Search for more papers by this author
  • Emilio Iannitto M.D.,

    1. Cattedra e Divisione di Ematologia con Trapianto di Midollo Osseo, Universitá di Palermo, Policlinico, Palermo, Italy
    Search for more papers by this author
  • Marco Paulli M.D.,

    1. Istituto di Anatomia Patologica, Universitá di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy
    Search for more papers by this author
  • Lorena Garioni M.D.,

    1. Istituto di Radiologia, Universitá di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy
    Search for more papers by this author
  • Edoardo Ascari M.D.

    1. Medicina Interna e Oncologia Medica, Universitá di Pavia, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo, Pavia, Italy
    Search for more papers by this author

Abstract

BACKGROUND

The authors investigated the clinical role of tumor burden (TB) in patients with Hodgkin lymphoma, relating this parameter to most of the current clinical and prognostic factors and to the best predictive multifactorial models.

METHODS

The volume of TB at diagnosis was measured directly from the initial staging computed tomography scans in 351 patients who were treated on standard protocols. The mean patient age was 34.0 years ± 16.4 years. Forty-six patients had clinical Stage I disease, 201 patients had Stage II disease, 64 patients had Stage III disease, and 40 patients had Stage IV disease. There were 146 symptomatic patients. Overall survival (OS), disease-free survival (DFS), and time to treatment failure (TTF) were the time parameters evaluated in the multivariate analysis. Logistic regression was applied according to those who achieved or failed complete remission.

RESULTS

The mean TB normalized to body surface area (rTB) was 137.8 cm3/m2 ± 124.7 cm3/m2 (range, 1.9–694.5 cm3/m2). In multivariate analysis, rTB was the best predictor of TTF, DFS, and complete remission; the second best predictor of OS after patient age; and largely superior to all prognostic models analyzed. For the same stage and treatment, patients who were destined to clinical failure had an initial rTB 60–108% higher compared with the initial rTB in patients who achieved a cure, whereas differences in drug dose intensity were not significant.

CONCLUSIONS

In the current study, it was found that the rTB, as a prognostic factor, was more effective than and was independent of hitherto used factors and scores. The rTB may be a tool for evaluating the curative potential of treatment combinations, allowing physicians and patients to make better therapeutic choices earlier. Cancer 2004. © 2004 American Cancer Society.

Ancillary